MIT researchers have developed a groundbreaking method for gene editing that significantly reduces errors, making gene therapy safer and more effective for treating genetic diseases. This innovative approach promises a future of precise genomic alterations with fewer side effects.
This week in science news, a breakthrough gene therapy shows promise in treating Huntington's disease, while a Vancouver man regains his sight through a revolutionary tooth-in-eye surgery. Additionally, Super Typhoon Ragasa wreaks havoc across Asia, and new studies reveal shocking links between pollution and health.
A groundbreaking gene therapy has shown it can slow the progression of Huntington's disease by 75% in a small clinical trial. This one-time treatment could reshape the future for patients with this rare brain disorder.
Scientists from University College London have made a groundbreaking discovery that could slow the progression of Huntington’s disease. A new gene therapy, AMT-130, shows promising results in clinical trials, potentially changing lives forever.
In a groundbreaking announcement, gene therapy company uniQure revealed an experimental treatment that has slowed the progression of Huntington's disease. Although still in early testing, this could signal new hope for patients battling this devastating condition.
In a surprising turn of events, the FDA has allowed Sarepta Therapeutics to resume shipments of its gene therapy, Elevidys, for younger Duchenne muscular dystrophy patients who can walk, despite concerns over previous fatalities.
As gene therapy for Duchenne muscular dystrophy faces scrutiny after tragic deaths, families like the Revells navigate the uncertain waters of hope and risk, questioning the future of their loved ones.
Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy is on hold due to safety issues. An FDA official warns the path to market approval is fraught with challenges, especially after patient deaths linked to liver injuries.
In a stunning move, the FDA has put clinical trials for Sarepta's gene therapy on hold due to alarming safety concerns after multiple patient deaths linked to acute liver failure. The company faces scrutiny as it navigates the fallout.
Sarepta Therapeutics is under fire as another patient succumbs to acute liver failure linked to its gene therapy trial for muscular dystrophy, adding to the recent deaths of two teenage boys.
